Letrozol – 1 A Pharma® 2,5 mg

Description

Side effects

Letrozole is fairly well tolerated in the first- and second-line treatment of advanced breast cancer, as well as in the adjunctive treatment of early breast cancer and in the treatment of breast cancer patients previously treated with standard tamoxifen therapy.

Almost one-third of patients treated with letrozole for metastases and in neoadjuvant therapy, about 80% of patients in adjuvant therapy (both groups received both letrozole and tamoxifen, median treatment duration was 60 months) and almost 80% of patients in extended adjuvant therapy (both letrozole and placebo, median treatment duration was 60 months) experienced adverse effects. The adverse effects observed were mostly of mild to moderate severity and were mostly related to oestrogen deficiency. The most commonly mentioned side effects in the clinical study reports were hot flashes, joint pain, nausea and fatigue. Many side effects may be due to the natural pharmacological consequences of oestrogen deficiency (e.g. hot flashes, alopecia or vaginal bleeding).